Related Experiment Videos
Epidermal growth factor receptor expression by acoustic neuromas
E M Sturgis1, S S Woll, F Aydin
1Department of Otolaryngology--Head and Neck Surgery, Tulane University School of Medicine, New Orleans, LA 70112-2699, USA.
The Laryngoscope
|April 1, 1996
Summary
Acoustic neuromas (ANs) express low levels of epidermal growth factor receptor (EGFr). This suggests that anti-EGFr therapies may not be clinically effective for treating ANs.
Area of Science:
- Oncology
- Neurosurgery
- Molecular Biology
Background:
- Epidermal growth factor receptor (EGFr) targeted therapies are effective against EGFr-positive cancers.
- Acoustic neuromas (ANs) are tumors affecting the cranial nerve.
Purpose of the Study:
- To evaluate the expression of EGFr in acoustic neuromas.
- To determine the potential efficacy of anti-EGFr therapies for ANs.
Main Methods:
- Retrospective review of AN patient records (1989-1994).
- Immunohistochemical analysis of archival surgical specimens for EGFr expression.
- Scoring of EGFr staining intensity in Antoni A and Antoni B areas by two pathologists.
Main Results:
- Acoustic neuromas demonstrated positive EGFr expression, predominantly at low levels.
- Antoni A areas showed higher EGFr staining intensity compared to Antoni B areas.
- Normal eighth cranial nerves exhibited minimal background staining.
Conclusions:
- Acoustic neuromas express low levels of EGFr, with higher expression in Antoni A regions.
- The clinical efficacy of anti-EGFr therapies for acoustic neuromas is questionable.
- Further studies are needed for precise EGFr quantification in ANs.